Page 99 - 《中国药房》2026年3期

曲普瑞林联合鳖甲煎丸治疗子宫腺肌病的临床观察
Δ

3
1＊
王秀萍 ，乔献伟 ，徐 冰（1.南阳市第一人民医院中医科，河南 南阳 473000；2.南阳市第一人民医院检验
2
科，河南 南阳 473000；3.南阳市第二人民医院中医妇科，河南 南阳 473012）
中图分类号 R711.71；R984 文献标志码 A 文章编号 1001-0408（2026）03-0361-05
DOI 10.6039/j.issn.1001-0408.2026.03.15

摘 要 目的 探讨曲普瑞林联合鳖甲煎丸治疗子宫腺肌病（AM）患者的临床效果。方法 选择2022年1月至2024年10月南阳市
第一人民医院收治的186例AM患者，按照随机数字表法分为对照组（93例）和观察组（93例）。对照组患者于脐周皮下注射醋酸
曲普瑞林；观察组患者在对照组治疗的基础上口服鳖甲煎丸。两组患者均治疗12周，治疗后随访6个月。比较两组患者的临床疗
效、复发、不良反应情况，以及治疗前后的中医证候积分、子宫内膜容受性（子宫内膜厚度、子宫体积、子宫内膜阻力指数和子宫内
膜血管指数）、实验室检查指标（黄体生成素、卵泡刺激素、雌二醇、糖类抗原125、胰岛素样生长因子1、基质金属蛋白酶9）水平。
结果 共有164例患者完成治疗和随访，其中对照组有80例，观察组有84例。观察组患者的总有效率显著高于对照组，低雌激素
发生率、复发率均显著低于对照组（P＜0.05）；两组患者恶心、肝肾功能异常的发生率比较，差异均无统计学意义（P＞0.05）。治疗
后，两组患者的疼痛视觉模拟评分、月经失血图评分、中医证候积分、子宫内膜厚度、子宫体积、子宫内膜阻力指数、实验室检查指
标均显著低于同组治疗前（P＜0.05），且观察组显著低于对照组（卵泡刺激素除外）（P＜0.05）；子宫内膜血管指数显著高于同组治
疗前，且观察组显著高于对照组（P＜0.05）。结论 曲普瑞林联合鳖甲煎丸治疗AM的疗效显著，可有效改善患者的痛经程度、月
经量和子宫内膜容受性，降低复发率，且安全性良好。
关键词 子宫腺肌病；曲普瑞林；鳖甲煎丸；疗效；子宫内膜容受性；复发

Clinical observation of triptorelin combined with Biejiajian pill in the treatment of adenomyosis
WANG Xiuping ，QIAO Xianwei ，XU Bing（1. Dept. of Traditional Chinese Medicine， Nanyang First People’s
3
2
1
Hospital， Henan Nanyang 473000， China；2. Clinical Laboratory， Nanyang First People’s Hospital， Henan
Nanyang 473000， China；3. Dept. of TCM Gynecology， Nanyang Second General Hospital， Henan Nanyang
473012， China）

ABSTRACT OBJECTIVE To investigate the clinical effectiveness of triptorelin combined with Biejiajian pill in the treatment of
adenomyosis （AM）. METHODS Totally 186 patients with AM admitted to Nanyang First People’s Hospital from January 2022 to
October 2024 were selected as subjects and randomized into control group （n＝93） and observation group （n＝93） using the
random number table method. Patients in the control group received subcutaneous injections of triptorelin acetate around the
umbilicus. In addition to the treatment of control group， patients in the observation group orally administered Biejiajian pill. Both
groups underwent treatment for 12 weeks and were followed up for 6 months post-treatment. The clinical efficacy， recurrence and
the occurrence of adverse drug reactions were compared between the two groups. Traditional Chinese medicine （TCM） symptoms，
endometrial receptivity indicators （endometrial thickness， uterine volume， endometrial resistance index and vascular index），
laboratory indexes （serum luteinizing hormone， follicle stimulating hormone， estradiol， carbohydrate antigen 125， insulin-like
growth factor-1， and matrix metalloproteinase 9） were compared between the two groups before and after treatment. RESULTS A
total of 164 patients completed the treatment and follow-up， among whom 80 cases were in control group and 84 cases in the
observation group. The overall effective rate in the observation group was significantly higher than that in the control group， while
the incidence of low estrogen levels and recurrence rate were significantly lower in the observation group compared to the control
group （P＜0.05）. There were no statistically significant differences in the incidence of nausea or abnormal liver and kidney function
between the two groups （P＞0.05）. After treatment， the pain Visual Analogue Scale scores， Pictorial Blood Loss Assessment
Chart， TCM symptoms scores， endometrial thickness， uterine volume， endometrial resistance index， and laboratory indicators in
both groups were significantly lower than those before treatment within the same group （P＜0.05）. Moreover， these values were
significantly lower in the observation group compared to the control group （except for follicle stimulating hormone） （P＜0.05）.
The endometrial vascular index of the two groups was
Δ 基金项目 河南省自然科学基金项目（No.242300420284）
＊第一作者 副主任中医师。研究方向：中医妇科不孕症。E-mail： significantly higher than that in the same group before
wangxping0377@163.com treatment， and the observation group was significantly higher

中国药房 2026年第37卷第3期 China Pharmacy 2026 Vol. 37 No. 3 · 361 ·